SCHEMBL13633602

SCHEMBL13633602

c1cc(-c2ccc(N3CCNCC3)s2)nc(N[C@H]2C[C@H]3CC[C@@H](C2)N3)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 6/20 0.42
MAPK8 P45983 3/20 0.42
PBK Q96KB5 2/20 0.42
HRH4 Q9H3N8 2/20 0.41
CDK9 P50750 5/20 0.39
CDK4 P11802 4/20 0.39
CCND1 P24385 4/20 0.39
CCNT1 O60563 4/20 0.39
CDK7 P50613 4/20 0.39
CCND3 P30281 3/20 0.39
CCNH P51946 3/20 0.39
CDK6 Q00534 3/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
MAPK1 P28482 1/20 0.39
CDK2 P24941 5/20 0.38
CCNA2 P20248 4/20 0.38
CDK1 P06493 3/20 0.38
CCNB1 P14635 3/20 0.38
CCNA1 P78396 1/20 0.37
CHEK1 O14757 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480721 1.00 IKBKB (0.42) IKBKBMAPK8PBKHRH4CDK9
SCHEMBL13633606 0.81 DGAT1 (0.47) MAPK8CDK9CDK4CCND1CDK7
SCHEMBL4498497 0.81 DGAT1 (0.47) MAPK8CDK9CDK4CCND1CDK7
SCHEMBL3470774 0.80 CDK9 (0.40) IKBKBMAPK8PBKHRH4CDK9
SCHEMBL13638422 0.77 CDK9 (0.40) IKBKBMAPK8PBKCDK9CDK4
SCHEMBL4473548 0.74 IKBKB (0.42) IKBKBMAPK8HRH4CDK9CDK4
SCHEMBL13633568 0.74 IKBKB (0.42) IKBKBMAPK8HRH4CDK9CDK4
SCHEMBL3472274 0.73 IKBKB (0.48) IKBKBMAPK8CDK9CCNT1CDK2
SCHEMBL13633647 0.73 IKBKB (0.48) IKBKBMAPK8CDK9CCNT1CDK2
SCHEMBL13633704 0.73 IKBKB (0.48) IKBKBMAPK8CDK9CCNT1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK IKBKB 2/4885MAPK8 197/4885PBK 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.